VTVT · NASDAQ
vTv Therapeutics Inc.
$21.72 -2.27 (-9.46%)
Company overview
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes, and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor for inflammatory diseases and psoriasis. It is also involved in clinical development of additional programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion in cystic fibrosis-related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases including severe COVID-19, as well as pancreatic and breast cancers; and HPP9…
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $85.9M
- Employees
- 23
- Headquarters
- High Point, NC
- Website
- vtvtherapeutics.com
- CEO
- Paul J. Sekhri
- Listed
- July 30, 2015
- P/E
- 1,086.00
- Dividend yield
- 0.00%
Company financials
- Revenue
- $36.8M
- Gross profit
- $36.8M
- Operating income
- -$3M
- EBITDA
- -$1.9M
- Net income
- $2.3M
- EPS
- $0.02
- Total assets
- $98.8M
- Total debt
- $0.00
- Gross margin
- 100.00%
- Net margin
- 6.11%
- Earnings yield
- 0.09%
No geographic segmentation.
Showing FY 2024
VTVT
1D
NASDAQ
O23.55H24.38L23.55C24.03+0.48 (+2.04%)Vol28.58K
News